What is it about?
P-glycoprotein (P-gp) plays a fundamental role in transporting Aβ from the brain to the blood and protecting the blood-brain barrier (BBB). The dysfunction or decreased abundance of this transporting protein is associated with the accumulation of Aβ, leading to dementia and cognitive deficits. Current evidence claims that p-gp is involved in AD pathology and that enhancing the activity of this transporter may be a promising therapeutic approach to hinder AD progression. There is also a growing interest in P-gp as a potential therapeutic target for AD. Hence, ongoing clinical trials and research should investigate P-gp inhibitor efficacy as a therapeutic approach for improving AD drug delivery to the brain and treatment outcomes.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
There is also a growing interest in P-gp as a potential therapeutic target for AD.
Perspectives
Ongoing clinical trials and research should investigate P-gp inhibitor efficacy as a therapeutic approach for improving AD drug delivery to the brain and treatment outcomes.
Hebatallah Atteia
Department of pharmaceutical chemistry, Faculty of pharmacy, University of Tabuk, Tabuk, Saudi Arabia; Department of Biochemistry, Faculty of pharmacy, Zagazig university, Zagazig, Egypt
Read the Original
This page is a summary of: P-glycoproteins in the Pathology and Treatment of Alzheimer's Disease, Letters in Drug Design & Discovery, December 2024, Bentham Science Publishers,
DOI: 10.2174/0115701808293022240216070603.
You can read the full text:
Contributors
The following have contributed to this page
